DTS Inc. (NASDAQ:DTSI) reported fourth quarter non-GAAP EPS of $0.34 after the bell Monday, down from $0.46 in the previous year. Analysts expected EPS of $0.32. Full year 2015 non-GAAP EPS is expected to be between $1.65 and $1.75. The consensus estimate is for EPS of $1.73. On Tuesday shares of DTS Inc. (NASDAQ:DTSI) closed at $33.72. Company’s sales growth for last 5 years was 15.80% and EPS growth for next 5 years is recorded as 20.00%.
Contango Oil & Gas Company (NYSEMKT:MCF) swung to a net loss for the quarter ended Dec. 31, 2014. The company has made a net loss of $19.93 million in the quarter, against a net profit of $6.40 million in the last year period. Revenue during the quarter dropped 24.92 percent to $50.23 million from $66.90 million in the previous year period. Operating margin for the quarter stood at negative 68 percent as compared to a positive 9.45 percent for the previous year period. Contango Oil & Gas Company (NYSEMKT:MCF) in last trading activity decreased -8.16% to close at $21.04. Company weekly performance is -14.44% while its quarterly performance stands at -37.77%. Contango Oil & Gas Company (NYSEMKT:MCF) is -58.29% away from its 52 week high.
On 27 february 2015, Northwest Natural Gas Company (NYSE:NWN) announced its Q4 and full year results for 2014, with net earnings coming to US$28.5 million in the fourth quarter and $58.7 million for the fiscal year. Consolidated earnings were $2.16 per share on net income of $58.7 million for fiscal year 2014, compared to $2.24 per share and $60.5 million for 2013. On last trading day Northwest Natural Gas Company (NYSE:NWN) moved up 1.02% to close at $46.57. Its volatility for the week is 2.28% while volatility for the month is 2.29%. NWN’s sales growth for past 5 years was -6.10% and its EPS growth for past 5 years was -3.00%. Northwest Natural Gas Company (NYSE:NWN) monthly performance is -6.69%.
Opexa Therapeutics, Inc. (NASDAQ: OPXA) on 24 February 2015, reported financial results for the year ended December 31, 2014 and provided an update on the Company’s recent corporate developments. For the year ended December 31, 2014, Opexa reported a net loss of $15.1 million, or $0.54 per share, compared to a net loss of $16.7 million, or $1.25 per share, for 2013. Research and development expense was $12.1 million, an increase of 32.0% compared to $9.2 million in 2013. Opexa Therapeutics, Inc. (NASDAQ:OPXA) has 0.40% insider ownership while its institutional ownership stands at 5.70%. In last trading activity company’s stock closed at $0.91.
FBR Capital Markets lowered shares of EPR Properties (NYSE:EPR) from an outperform rating to a market perform rating in a report released on 25 February 2015. On last trading day EPR Properties (NYSE:EPR) decreased -0.13% to close at $60.54. Its volatility for the week is 2.71% while volatility for the month is 2.19%. EPR’s sales growth for past 5 years was 5.40% and its EPS growth for past 5 years was -0.20%. EPR Properties (NYSE:EPR) monthly performance is -6.49%.